FindTrial
Sign In

Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations

Expanded Access Use of Derazantinib for Patients With Locally Advanced, Inoperable or Metastatic iCCA Harbouring FGFR Genomic Alterations

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT04087876
Enrollment
Unknown
Registered
2019-09-12
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrahepatic Cholangiocarcinoma

Keywords

intrahepatic cholangiocarcinoma, iCCA, Metastatic cholangiocarcinoma, FGFR genomic alteration, biliary cancer, bile duct cancer, liver cancer

Brief summary

Basilea provided expanded access to derazantinib for patients with locally advanced, inoperable or metastatic intrahepatic cholangiocarcinoma (iCCA) with FGFR genomic alterations on a patient by patient basis while clinical development of derazantinib was ongoing.

Interventions

DRUGderazantinib

derazantinib will be administered orally

Sponsors

Basilea Pharmaceutica
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

The following inclusion criteria were applied: * all other treatment options had been exhausted * patient was ineligible for any ongoing trials or was geographically inaccessible to trials including a trial with derazantinib * there was a reason to believe that the potential benefit of receiving derazantinib outweighs the risk of treatment with an investigational drug product * patient was willing and able to provide written informed consent * if applicable, regulatory approval by the appropriate jurisdiction was obtained

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026